Please assess the completion status of the following clinical trial:

Trial Title: NMDA Antagonists in Bipolar Depression

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female patients with Diagnostic and Statistical Manual, Version 4 (DSM-IV) diagnosis of bipolar disorder I or II, current major depressive episode without psychotic features, 18-60~* Insufficient therapeutic response during the current episode~* Medically stable for study participation~* Judged clinically not to be at significant suicide or violence risk~* Subject is off all psychotropic and other types of drugs likely to interact with glutamate for at least 14 days before starting the study. One exception is chloral hydrate or short acting benzodiazepines for distressing anxiety or insomnia (up to 72 hours prior to each MRI scan). In addition, subjects will be off antipsychotics for 1 month and off fluoxetine for 6 weeks prior to the study.~* Subject is likely to be able to tolerate a medication washout. Only subjects who have failed their current medication regiment will be washed off medications.~Exclusion Criteria:~* History of chronic psychosis or drug induced psychosis of any kind~* Current DSM-IV diagnosis of drug abuse/dependence in the last six months. Subjects must have a negative drug screen at baseline.~* Women will be excluded if they are pregnant lactating, or not either surgically-sterile or using appropriate methods of birth control. Women must agree to continue using applicable birth control throughout the trial. All women of child-bearing potential must have a negative urine pregnancy test~* Taking any medication contraindicated with ketamine or DCS (ethionamide, isoniazid)~* History of seizures, renal insufficiency or congestive heart failure~* History of clinically significant violence~* History of ketamine abuse/dependence or prior clinically significant adverse reaction to ketamine~* Current alcohol abuse or dependence~* Untreated hypertension~* Clinically abnormal liver function tests (LFTs), thyroid, renal function or anemia~* Metal implants, pacemaker, other metal (e.g. shrapnel or surgical prostheses) or paramagnetic objects contained within the body which may present a risk to the subject or interfere with the MR scan.~* Medicinal patch, unless removed prior to the MR scan

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Ketamine and DCS treatment (Type: EXPERIMENTAL): Standard of Care: Subjects will receive treatment with either quetiapine, olanzapine-fluoxetine, or lurasidone. If after about 2 week, subjects are symptomatic, subjects will receive infusion of ketamine hydrochloride (0.5 mg/kg). After the ketamine phase, subject who show improvement will begin an 8-week treatment of oral D-cycloserine.

Based on this trial design, predict the completion outcome and termination type (if applicable).